INTRODUCTION: Over the past three decades, oral controlled release dosage forms have been created due to their significant therapeutic benefits, including simplicity of administration, patient compliance, and formulation flexibility. Floating drug delivery system (FDDS) is one of the most practical methods for generating a prolonged predictable drug delivery profile since it extends the stomach residence period and boosts the dosage form's overall bioavailability.. MATERIALS AND METHODS: The Ganciclovir is used in this trial was manufactured as a floating tablet. Three formulations were made. Drug concentration is constant in each formulation whereas excipient concentration varies. The formulation employed the direct compression method. Other common excipients were combined with other polymers, including HPMC K 15, HPMC K 100, and MCC. Effervescent agent was sodium bicarbonate. The prepared powder blend's preformulation properties, including true density, bulk density, compressibility index, angle of repose, and Hausner's ratio, were assessed. Hardness, friability, weight fluctuation, thickness, drug content, swelling study, floating time, and in vitro dissolution analysis were all examined as physical characteristics of the tablet. RESULTS AND DISCUSSION: The preformulation study's findings demonstrated that the powder blend's good flow characteristics and packing potential. All 3 formulations (F1 to F3) demonstrated good mechanical strength and complied with pharmacopoeial standards, according to the findings of the hardness and friability test. The improved formulation F3 met the standards with a drug release of 94.03±.2.05 %, a floating lag time of 1.39 min, and a total floating time of >14 h. Overall findings indicated that the formulation meets the criteria needed for an effective floating medication delivery system.. CONCLUSION: The findings of this study clearly demonstrate the viability of creating a drug delivery system for ganciclovir that prolongs the time the drug is retained in the stomach while allowing for regulated release.